NCT02257424View on ClinicalTrials.gov

Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

October 31, 2021

Study Completion Date

October 31, 2021

Conditions
Advanced BRAF Mutant Melanoma
Interventions
DRUG

Trametinib 2 mg daily

DRUG

hydroxychloroquine (HCQ)

hydroxychloroquine (HCQ) is 600 mg orally every 12 hours

DRUG

dabrafenib 150 mg orally twice a day

Trial Locations (4)

19104

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

60611

Robert H. Lurie Comprehensive Cancer Center, Chicago

63110

Washington University School of Medicine, St Louis

08903

Rutgers Cancer Institute of New Jersey, New Brunswick

All Listed Sponsors
lead

Abramson Cancer Center at Penn Medicine

OTHER

NCT02257424 - Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma | Biotech Hunter | Biotech Hunter